[go: up one dir, main page]

MA28436B1 - Modulateurs selectifs du recepteur des oestrogenes pour le traitement de symptômes vasomoteurs - Google Patents

Modulateurs selectifs du recepteur des oestrogenes pour le traitement de symptômes vasomoteurs

Info

Publication number
MA28436B1
MA28436B1 MA29277A MA29277A MA28436B1 MA 28436 B1 MA28436 B1 MA 28436B1 MA 29277 A MA29277 A MA 29277A MA 29277 A MA29277 A MA 29277A MA 28436 B1 MA28436 B1 MA 28436B1
Authority
MA
Morocco
Prior art keywords
symptoms
estrogen receptor
vasomote
treatment
selective modulators
Prior art date
Application number
MA29277A
Other languages
English (en)
Inventor
Robert Dean Dally
Jeffrey Alan Dodge
Scott Alan Frank
Ronald Jay Hinklin
Timothy Alan Shepherd
Owen Brendan Wallace
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA28436B1 publication Critical patent/MA28436B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/092—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings with aromatic radicals attached to the chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention se rapporte à un modulateur de récepteur d'oestrogène sélectif de formule I: ou à son sel d'addition d'un acide pharmaceutique ; utile pour traiter les symptômes vasomoteurs.
MA29277A 2004-01-22 2006-08-18 Modulateurs selectifs du recepteur des oestrogenes pour le traitement de symptômes vasomoteurs MA28436B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53834204P 2004-01-22 2004-01-22
US53844204P 2004-01-22 2004-01-22

Publications (1)

Publication Number Publication Date
MA28436B1 true MA28436B1 (fr) 2007-02-01

Family

ID=34830456

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29277A MA28436B1 (fr) 2004-01-22 2006-08-18 Modulateurs selectifs du recepteur des oestrogenes pour le traitement de symptômes vasomoteurs

Country Status (20)

Country Link
US (2) US20090023917A1 (fr)
EP (1) EP1709021B1 (fr)
JP (1) JP4909086B2 (fr)
KR (2) KR100849559B1 (fr)
CN (1) CN102250042A (fr)
AT (1) ATE476428T1 (fr)
AU (1) AU2005207821B2 (fr)
BR (1) BRPI0506721A (fr)
CA (1) CA2551956C (fr)
CR (1) CR8517A (fr)
DE (1) DE602005022673D1 (fr)
EA (2) EA016613B1 (fr)
EC (1) ECSP066711A (fr)
ES (1) ES2347973T3 (fr)
IL (1) IL176738A0 (fr)
MA (1) MA28436B1 (fr)
NO (1) NO20063760L (fr)
SG (1) SG149867A1 (fr)
UA (1) UA85862C2 (fr)
WO (1) WO2005073204A1 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2037905B1 (fr) 2006-06-23 2013-05-01 Radius Health, Inc. Traitement de symptômes vasomoteurs par des modulateurs des récepteurs d' strogène sélectifs
WO2008009079A2 (fr) * 2006-07-20 2008-01-24 Gilead Sciences, Inc. Ptéridines substituées utilisables pour le traitement et la prévention des infections virales
US9259426B2 (en) 2006-07-20 2016-02-16 Gilead Sciences, Inc. 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
EA020742B1 (ru) * 2008-09-29 2015-01-30 Эли Лилли Энд Компани Селективный модулятор рецепторов эстрогена
US20100087402A1 (en) * 2008-09-29 2010-04-08 Vivus, Inc. Methods and compositions for the treatment of estrogen-dependent hyperproliferative uterine disorders
US20100317635A1 (en) 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
EP3106159A1 (fr) 2010-05-12 2016-12-21 Radius Health, Inc. Régimes thérapeutiques
JP5965909B2 (ja) 2010-09-28 2016-08-10 ラジウス ヘルス，インコーポレイテッド 選択的アンドロゲン受容体モジュレーター
FR3014434B1 (fr) * 2013-12-05 2015-12-25 Servier Lab Nouveau procede de synthese du 7-methoxy-naphtalene-1-carbaldehyde et application a la synthese de l'agomelatine
FR3014437B1 (fr) * 2013-12-05 2016-12-23 Servier Lab Nouveau procede de synthese de l'agomelatine
CA2943611A1 (fr) 2014-03-28 2015-10-01 Duke University Methode de traitement du cancer faisant intervenir des modulateurs selectifs des recepteurs des ƒstrogenes
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
EP3722297A1 (fr) 2015-03-04 2020-10-14 Gilead Sciences, Inc. Composés modulateurs de récepteurs de type toll
CA3027563C (fr) 2016-06-22 2024-07-02 Ellipses Pharma Ltd Methodes ar+ de traitement du cancer du sein
PT3507276T (pt) 2016-09-02 2022-01-11 Gilead Sciences Inc Compostos moduladores do recetor de tipo toll
EP3507288B1 (fr) 2016-09-02 2020-08-26 Gilead Sciences, Inc. Dérivés de 4,6-diamino-pyrido[3,2-d]pyrimidine en tant que modulateurs du recepteur de type toll
JP7481115B2 (ja) 2017-01-05 2024-05-10 ラジウス ファーマシューティカルズ，インコーポレイテッド Ｒａｄ１９０１－２ｈｃｌの多形性形態
CN108675999B (zh) * 2018-05-09 2021-03-16 浙江农林大学暨阳学院 一种醋酸铜催化制备8-(9-亚砜基-10-二氢菲)喹啉类化合物的方法
IL279853B2 (en) 2018-07-04 2025-01-01 Radius Pharmaceuticals Inc Polymorphic forms of RAD 1901-2HCL
TWI702219B (zh) * 2018-07-12 2020-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑
WO2020014440A1 (fr) 2018-07-12 2020-01-16 Eli Lilly And Company Agents de dégradation sélectifs du récepteur des oestrogènes
CN119390714A (zh) 2019-02-12 2025-02-07 雷迪厄斯制药公司 方法和化合物
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI879779B (zh) 2019-06-28 2025-04-11 美商基利科學股份有限公司 類鐸受體調節劑化合物的製備方法
TWI894443B (zh) 2021-03-16 2025-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑
AU2023216654B2 (en) 2022-02-01 2025-09-25 Eli Lilly And Company Processes for the preparation of selective estrogen receptor degraders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998401A (en) * 1995-02-28 1999-12-07 Eli Lilly And Company Naphthyl compounds, intermediates, compositions, and methods
US5726186A (en) * 1995-09-08 1998-03-10 Eli Lilly And Company Pentacyclic compounds, intermediates, processes, compositions, and methods
ID19392A (id) * 1996-08-29 1998-07-09 Lilly Co Eli Senyawa naftil dan bahan pertengahan serta komposisi dan metode penggunaan
CA2213810C (fr) * 1996-08-29 2006-06-06 Lewis Dale Pennington Benzo¬b|thiophenes, intermediaires, procedes, compositions et methodes
CA2217810A1 (fr) * 1996-10-10 1998-04-10 Eli Lilly And Company Composes 2-aryl-3-aminoaryloxynaphtyliques, intermediaires, compositions et methodes
US5916916A (en) * 1996-10-10 1999-06-29 Eli Lilly And Company 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods
ATE295834T1 (de) * 1997-08-07 2005-06-15 Lilly Co Eli 1-(4-substituierte alkoxy)benzylnaphthalinderivate als östrogeninhibitoren
DE60327931D1 (de) * 2002-07-22 2009-07-23 Lilly Co Eli Selektive östrogenrezeptor modulatoren, die eine phenylsulfonyl-gruppe enthalten

Also Published As

Publication number Publication date
KR100849559B1 (ko) 2008-07-31
NO20063760L (no) 2006-10-16
EA200601353A1 (ru) 2007-02-27
EA016613B1 (ru) 2012-06-29
BRPI0506721A (pt) 2007-05-02
AU2005207821A1 (en) 2005-08-11
CA2551956C (fr) 2013-05-07
ECSP066711A (es) 2006-10-31
JP4909086B2 (ja) 2012-04-04
JP2007519721A (ja) 2007-07-19
EP1709021A1 (fr) 2006-10-11
AU2005207821B2 (en) 2011-02-10
EP1709021B1 (fr) 2010-08-04
US20110281847A1 (en) 2011-11-17
CA2551956A1 (fr) 2005-08-11
SG149867A1 (en) 2009-02-27
ATE476428T1 (de) 2010-08-15
DE602005022673D1 (de) 2010-09-16
WO2005073204A1 (fr) 2005-08-11
KR101008804B1 (ko) 2011-01-14
KR20080016755A (ko) 2008-02-21
US8217032B2 (en) 2012-07-10
CR8517A (es) 2006-12-01
ES2347973T3 (es) 2010-11-26
EA200900586A1 (ru) 2009-08-28
EA012262B1 (ru) 2009-08-28
IL176738A0 (en) 2006-10-31
CN102250042A (zh) 2011-11-23
US20090023917A1 (en) 2009-01-22
UA85862C2 (uk) 2009-03-10
KR20060129277A (ko) 2006-12-15

Similar Documents

Publication Publication Date Title
MA28436B1 (fr) Modulateurs selectifs du recepteur des oestrogenes pour le traitement de symptômes vasomoteurs
EA200870424A1 (ru) Способы применения рецептора gpr119 для идентификации соединений, которые можно использовать для увеличения костной массы субъекта
ATE548039T1 (de) Kondensierte heteroarylpyridyl- und phenylbenzensulfonamide als ccr2-modulatoren zur behandlung von entzündungen
MA35096B1 (fr) Cyclopropylamines en tant qu'inhibiteurs de lsd1
EA201170043A1 (ru) Комбинация пилокарпина и метимазола для лечения заболевания шарко-мари-тута и связанных с ним нарушений
FR3004920B1 (fr) Dispositif d'osteotomie, en particulier pour la realisation du scarf extreme dans le traitement de l'hallux valgus severe.
MY149855A (en) Benzimidazole derivatives and their use for modulating the gaba? receptor complex
MA35945B1 (fr) Inhibiteurs de la bêta-sécrétase
MA35455B1 (fr) (wo2013045407) dérivés d'estra-1,3,5(10),16-tétraène-3-carboxamide, procédé pour leur fabrication, préparations pharmaceutiques contenant ces substances ainsi que leur utilisation dans la fabrication de médicaments
ATE523497T1 (de) Neue 2-(2-hydroxyphenyl)benzimidazole, die sich für die behandlung von obesitas und diabetes eignen
MA35513B1 (fr) Compositions pharmaceutiques comprenant 40 - o - ( 2 - hydroxy) éthyl - rapamycine
TN2012000028A1 (en) 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl derivatives, methods for the production thereof and use thereof for treating diseases
NO20084792L (no) Substituerte imidazol-4-karboksamider som kolecystokinin-1-reseptormodulatorer
TN2016000040A1 (fr) Inhibiteurs de porc2 et procedes pour leur utilisation
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
MA34545B1 (fr) Co-cristaux et sels d'inhibiteurs de ccr3
EP2069377A4 (fr) Procédés et compositions pour le traitement de maladies et de troubles de la peau
TW200738669A (en) Crystalline forms of N-(benzo[b]thien-3-ylmethyl)-sulfamide
MY157425A (en) Substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses
EA201491614A1 (ru) Способ лечения гинекологических заболеваний
ATE473741T1 (de) Neue imidazolopyrazolderivate als selektive androgen-rezeptor-modulatoren
ATE482195T1 (de) Benzoäfüisoindole als antagonisten des ep4- rezeptors
EP2500409A4 (fr) Dispositif permettant de moduler l'expression de pgc-1, et dispositif de traitement et méthode de traitement pour maladie ischémique
ATE448215T1 (de) Selektive östrogen-rezeptor-modulatoren
EA200702604A1 (ru) Производные бензофуранона как нестероидные модуляторы рецептора прогестерона